Stocks to Watch: Nike, AAR, Mission Produce
By Ben Glickman
Nike now expects revenue to rise 1% for the full year ending in May, compared with previous expectations of mid-single digit growth. The company said it expects revenue in the current quarter to fall slightly, after reporting second-quarter revenue in line with Wall Street's estimates and announcing $2 billion in cost cuts over three years. Shares fall 11% to $108.86 after-hours.
AAR's profit rose slightly in the fiscal second quarter but missed analysts' estimates. The company's sales sank under 1% from a year ago despite higher demand in the aviation services company's parts supply business. Shares fall 3.8% to $68.10 after-hours.
Mission Produce said it is expecting slightly lower volumes of avocados in the current quarter due to a light Mexican harvest, as well as a slight sequential decline in selling price. The company swung to a profit in the fiscal fourth quarter, boosted by higher prices. Shares fall 3.1% to $9.27 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 18:43 ET (23:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging